No Data
Veritas In Silico Announces Strategic Organizational Reforms
Veritas In Silico Announces Director Reappointments and Board Member Elections
In the fiscal year ending December 2024, VIS will promote mRNA-targeted small molecule drug discovery business and the creation of its own pipeline.
Veritas In Silico <130A> announced its fiscal results for the year ending December 2024 on the 13th. Business revenue decreased by 46.0% compared to the previous year to 0.194 billion yen, with an operating loss of 0.212 billion yen (compared to a profit of 0.037 billion yen in the previous term), an ordinary loss of 0.233 billion yen (compared to a profit of 0.035 billion yen in the previous term), and a net loss of 0.236 billion yen (compared to a profit of 0.033 billion yen in the previous term). In the company's mRNA-targeted small molecule drug discovery business, the drug discovery platform ibVIS(R) is being utilized, and TORAY INDS INC <3402>.
Veritas In Silico Inc. Expands MRNA Drug Discovery Efforts
Veritas In Silico Inc. Reports Financial Losses for 2024, Anticipates Recovery in 2025
Veritas In Silico: Financial results presentation materials for the fiscal year ending 2024/12